iShares Biotechnology ETF
893 hedge funds and large institutions have $5.4B invested in iShares Biotechnology ETF in 2022 Q1 according to their latest regulatory filings, with 81 funds opening new positions, 258 increasing their positions, 330 reducing their positions, and 132 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
15% less capital invested
Capital invested by funds: $6.37B → $5.4B (-$978M)
22% less repeat investments, than reductions
Existing positions increased: 258 | Existing positions reduced: 330
39% less first-time investments, than exits
New positions opened: 81 | Existing positions closed: 132
Holders
893
Holding in Top 10
13
Calls
$285M
Puts
$254M
Top Buyers
| 1 | +$86.4M | |
| 2 | +$63.7M | |
| 3 | +$51.5M | |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
+$51.4M |
| 5 |
Citigroup
New York
|
+$49.1M |
Top Sellers
| 1 | -$107M | |
| 2 | -$94.4M | |
| 3 | -$73.8M | |
| 4 |
Two Sigma Advisers
New York
|
-$38M |
| 5 |
Two Sigma Investments
New York
|
-$34.9M |